Parent Drug Name | Name of Impurity | Catalogue No. | |
---|---|---|---|
Bilastine | Bilastine Impurity 10 | VE0012685 | View CAS 1181267-38-8 |
Bilastine | Bilastine Impurity 11 | VE0012688 | View CAS 1181267-33-3 |
Bilastine | Bilastine Impurity 12 | VE0012692 | View CAS 202189-77-3 |
Bilastine | Bilastine Impurity 13 | VE0012693 | View CAS 1638785-19-9 |
Bilastine | Bilastine Impurity 14 DiHCl | VE0012698 | View |
Bilastine | Bilastine Impurity 15 | VE0012696 | View CAS 1215537-40-8 |
Bilastine | Bilastine Impurity 16 | VE0012697 | View |
Bilastine | Bilastine Impurity 17 | VE0012699 | View CAS 202189-83-1 |
Bilastine | Bilastine Impurity 18 | VE0012700 | View CAS 2411093-91-7 |
Bilastine | Bilastine Impurity 2 | VE0012707 | View CAS 1181267-36-6 |
Bilastine | Bilastine Impurity 21 | VE0012705 | View CAS 38385-95-4 |
Bilastine | Bilastine Impurity 22 | VE0012706 | View CAS 202189-81-9 |
Bilastine | Bilastine Impurity 4 | VE0012714 | View |
Bilastine | Bilastine Impurity 5 | VE0012672 | View |
Bilastine | Bilastine Impurity 6 | VE0012673 | View |
Bilastine | Bilastine Impurity 7 | VE0012674 | View CAS 110963-63-8 |
Bilastine Impurity | Bilastine N- Oxide | VE005902 | View CAS 2069238-47-5 |
Bilastine | Bilastine Nitroso Impurity 1 | VE0010708 | View CAS 2731008-04-9 |
Bilastine | Bilastine Nitroso Impurity 3 | VE0010709 | View |
Bilastine | 1’-Hydroxy Bilastine | VE0011468 | View CAS 1638785-23-5 |
Bilastine | 2747918-37-0: Bilastine-D4 | DVE00598 | View CAS 2747918-37-0 |
Bilastine Related Compound
It is also effective in treating itchy skin rashes (wheals or urticaria).
References
- Lavorini, Federico, et al. “Concomitant Bilastine and Montelukast as Additive Therapy for Seasonal Allergic Rhinoconjunctivits and Mild‐To‐Moderate Asthma. The SKY Study.” Allergy, vol. 75, no. 3, Wiley-Blackwell, Oct. 2019, pp. 675–77, https://doi.org/10.1111/all.14007. Accessed 25 Aug. 2023.
- Murali, G., and Alaric J. Dyckman. Evolution of Small-Molecule Immunology Research—Changes since CMC II. Jan. 2017, https://doi.org/10.1016/b978-0-12-409547-2.12401-1. Accessed 25 Aug. 2023.
- Wolthers, Ole D. “Bilastine: A New Nonsedating Oral H1 Antihistamine for Treatment of Allergic Rhinoconjunctivitis and Urticaria.” BioMed Research International, vol. 2013, Hindawi Publishing Corporation, Jan. 2013, pp. 1–6, https://doi.org/10.1155/2013/626837. Accessed 25 Aug. 2023.
FAQ
What is the therapeutic use of blasting?
Bilastine is an antihistamine used to treat allergic rhinitis and urticaria. Because bilastine is a second-generation H1-antihistamine with low CNS penetration, it prevents the sedative properties of first-generation antihistamines.
What class of drug is blasting?
Non-sedating antihistamines belong to a very diverse pharmacological class. Bilastine is not structurally related to other antihistamines. It, like loratadine, desloratadine, and fexofenadine, belongs to the piperidine class of antihistamines.
Is blasting used for asthma?
Additive treatment with bilastine and montelukast for seasonal allergy rhinoconjunctivitis and mild to moderate asthma.